We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SLQT Q4 Earnings Call Puts Cash Flow Ahead of MA Growth
Read MoreHide Full Article
Key Takeaways
SelectQuote expects fiscal 2027 revenues of $1.35B-$1.45B and more than $60M in operating cash flow.
SLQT expects MA approved policies to decline 10-15%, while Senior margins remain above the 20% target.
SelectRx exited fiscal 2026 at a nearly $50M annual adjusted EBITDA run rate as pharmacy efficiency improved.
SelectQuote, Inc. (SLQT - Free Report) used its fourth-quarter fiscal 2026 earnings call to put cash generation and leverage reduction ahead of near-term growth. Revenues for the reported quarter were $321.7 million, which missed the Zacks Consensus Estimate of $375 million. The company incurred a loss of 19 cents per share, wider than the Zacks Consensus Estimate of a loss of 15 cents.
SelectQuote, Inc. Price, Consensus and EPS Surprise
Management focused on fiscal 2027, when it expects lower revenues, but materially higher operating cash flow as pharmacy margins improve and cost actions take hold.
SLQT Makes Cash Flow the Core Priority
Tim Danker, CEO and director, said profitable cash flow is the company's highest priority, with operating efficiency and lower leverage central to building shareholder value.
Ryan Clement, CFO, said fiscal 2026 operating cash flow improved by $44 million year over year to $31.9 million. For fiscal 2027, SelectQuote expects more than $60 million of operating cash flow and around $50 million of free cash flow.
Fourth-quarter adjusted EBITDA rose to $11.9 million from $2.7 million a year earlier even as revenue declined from $345.1 million.
SelectQuote Keeps MA Growth Disciplined
Danker said Medicare Advantage remains fluid as carriers work toward 3% to 4% operating margins. He expects continued plan terminations and benefit pullbacks while carrier profitability normalizes.
Clement said fiscal 2027 MA approved policies are expected to decline 10% to 15% year over year. Senior margins are expected to stay above the company's 20% target.
A Craig-Hallum analyst asked whether improving carrier signals could create upside. Danker said the market is healing, but pointed to plan year 2028 for a return to more responsible or targeted carrier growth.
SLQT Pushes Pharmacy Efficiency
Danker said Healthcare Services became SelectQuote's largest revenue contributor in fiscal 2026. SelectRx exited the year at a nearly $50 million annual adjusted EBITDA run rate.
Robert Grant, president, said the pharmacy facility in Olathe, Kan., is about 30% more efficient on shipments than legacy sites. Management also highlighted a custom pharmacy system and AI-enabled tools supporting more than $30 million of annual expense savings.
An RBC Capital Markets analyst asked about SelectRx growth outside Senior cross-selling. Grant said fiscal 2027 will prioritize margin and cash-flow efficiency, creating room to test third-party customer acquisition as economics improve.
SelectQuote Guides for Lower Revenues, Better Cash
Clement guided fiscal 2027 revenues to $1.35 billion to $1.45 billion and adjusted EBITDA to $90 million to $115 million. Revenues at the midpoint would be 14% below fiscal 2026.
Healthcare Services revenues are expected to fall 10-5%, primarily because of the Inflation Reduction Act. Clement said the revenue impact is more significant than the EBITDA impact and expects segment margins to approximately double.
Clement also expects SelectRx membership to finish fiscal 2027 around fiscal 2026 levels. Consolidated adjusted EBITDA margin is expected to expand about 60 basis points at the guidance midpoint.
SLQT Q&A Centers on Deleveraging
A NOBLE Capital Markets analyst pressed management on the more than $1 billion commissions receivable balance and longer-term cash generation. Clement said the balance should remain relatively flat through fiscal 2027 as collections are replenished by new policies.
Danker said debt and preferred equity total around $800 million at an approximate 12% cost. A 100-basis-point reduction in that funding cost would translate to nearly $8 million of savings.
When NOBLE asked about securitization and capital allocation, Clement said the short-term probability of another receivables securitization is relatively low. He prioritized deleveraging and high-return investments that enhance cash generation.
SelectQuote Ends on Execution Discipline
Danker closed by emphasizing cash flow over growth for its own sake. The fiscal 2027 plan centers on efficiency, disciplined Senior investment and stronger Healthcare Services profitability.
Clement's outlook pairs lower top-line expectations with higher cash generation, while management keeps refinancing, debt reduction and funding-cost optimization in focus.
The Style Scores complement the Zacks Rank, with A and B grades preferred and the strongest combinations generally pairing those scores with a Zacks Rank #1 or 2 (Buy). SLQT's Zacks Rank can change as earnings estimates are revised after the newly reported results.
View the Zacks #1 Rank List
Image: Bigstock
SLQT Q4 Earnings Call Puts Cash Flow Ahead of MA Growth
Key Takeaways
SelectQuote, Inc. (SLQT - Free Report) used its fourth-quarter fiscal 2026 earnings call to put cash generation and leverage reduction ahead of near-term growth. Revenues for the reported quarter were $321.7 million, which missed the Zacks Consensus Estimate of $375 million. The company incurred a loss of 19 cents per share, wider than the Zacks Consensus Estimate of a loss of 15 cents.
SelectQuote, Inc. Price, Consensus and EPS Surprise
SelectQuote, Inc. price-consensus-eps-surprise-chart | SelectQuote, Inc. Quote
Management focused on fiscal 2027, when it expects lower revenues, but materially higher operating cash flow as pharmacy margins improve and cost actions take hold.
SLQT Makes Cash Flow the Core Priority
Tim Danker, CEO and director, said profitable cash flow is the company's highest priority, with operating efficiency and lower leverage central to building shareholder value.
Ryan Clement, CFO, said fiscal 2026 operating cash flow improved by $44 million year over year to $31.9 million. For fiscal 2027, SelectQuote expects more than $60 million of operating cash flow and around $50 million of free cash flow.
Fourth-quarter adjusted EBITDA rose to $11.9 million from $2.7 million a year earlier even as revenue declined from $345.1 million.
SelectQuote Keeps MA Growth Disciplined
Danker said Medicare Advantage remains fluid as carriers work toward 3% to 4% operating margins. He expects continued plan terminations and benefit pullbacks while carrier profitability normalizes.
Clement said fiscal 2027 MA approved policies are expected to decline 10% to 15% year over year. Senior margins are expected to stay above the company's 20% target.
A Craig-Hallum analyst asked whether improving carrier signals could create upside. Danker said the market is healing, but pointed to plan year 2028 for a return to more responsible or targeted carrier growth.
SLQT Pushes Pharmacy Efficiency
Danker said Healthcare Services became SelectQuote's largest revenue contributor in fiscal 2026. SelectRx exited the year at a nearly $50 million annual adjusted EBITDA run rate.
Robert Grant, president, said the pharmacy facility in Olathe, Kan., is about 30% more efficient on shipments than legacy sites. Management also highlighted a custom pharmacy system and AI-enabled tools supporting more than $30 million of annual expense savings.
An RBC Capital Markets analyst asked about SelectRx growth outside Senior cross-selling. Grant said fiscal 2027 will prioritize margin and cash-flow efficiency, creating room to test third-party customer acquisition as economics improve.
SelectQuote Guides for Lower Revenues, Better Cash
Clement guided fiscal 2027 revenues to $1.35 billion to $1.45 billion and adjusted EBITDA to $90 million to $115 million. Revenues at the midpoint would be 14% below fiscal 2026.
Healthcare Services revenues are expected to fall 10-5%, primarily because of the Inflation Reduction Act. Clement said the revenue impact is more significant than the EBITDA impact and expects segment margins to approximately double.
Clement also expects SelectRx membership to finish fiscal 2027 around fiscal 2026 levels. Consolidated adjusted EBITDA margin is expected to expand about 60 basis points at the guidance midpoint.
SLQT Q&A Centers on Deleveraging
A NOBLE Capital Markets analyst pressed management on the more than $1 billion commissions receivable balance and longer-term cash generation. Clement said the balance should remain relatively flat through fiscal 2027 as collections are replenished by new policies.
Danker said debt and preferred equity total around $800 million at an approximate 12% cost. A 100-basis-point reduction in that funding cost would translate to nearly $8 million of savings.
When NOBLE asked about securitization and capital allocation, Clement said the short-term probability of another receivables securitization is relatively low. He prioritized deleveraging and high-return investments that enhance cash generation.
SelectQuote Ends on Execution Discipline
Danker closed by emphasizing cash flow over growth for its own sake. The fiscal 2027 plan centers on efficiency, disciplined Senior investment and stronger Healthcare Services profitability.
Clement's outlook pairs lower top-line expectations with higher cash generation, while management keeps refinancing, debt reduction and funding-cost optimization in focus.
SLQT's Zacks Signals Stay Mixed
SLQT carries a Zacks Rank #3 (Hold), with a Value Score of B, Growth Score of F, Momentum Score of A and VGM Score of C. Under the Zacks framework, Value is the strongest element and Momentum the weakest. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Style Scores complement the Zacks Rank, with A and B grades preferred and the strongest combinations generally pairing those scores with a Zacks Rank #1 or 2 (Buy). SLQT's Zacks Rank can change as earnings estimates are revised after the newly reported results.